Montelucaste Eurogenus (Montelukast Sodium)

Montelukast Sodium, the active ingredient in Montelucaste Eurogenus, is a leukotriene receptor antagonist presented as an oral dosage form for oral use. It is used to manage asthma, allergic rhinitis and exercise‑induced bronchoconstriction in patients requiring control of leukotriene‑mediated airway inflammation.

GNH USA supplies Montelucaste Eurogenus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast Sodium works on the leukotriene pathway to reduce airway inflammation and bronchoconstriction. - Asthma: improves control of chronic asthma and reduces the frequency of exacerbations. - Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes caused by seasonal allergies. - Exercise‑induced bronchoconstriction: prevents narrowing of the airways during or after physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain often reported. - Abdominal pain: discomfort or cramps in the stomach area. - Cough: occasional irritation of the throat. - Sore throat: mild irritation or scratchiness. - Nausea: feeling of queasiness. - Diarrhoea: loose stools.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema or anaphylaxis. - Neuropsychiatric events: agitation, depression, suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests. - Stevens‑Johnson syndrome: severe skin blistering. - Blood dyscrasias: rare blood cell abnormalities.

Before using Montelukast, consider the following safety measures. - Pregnancy: consult a healthcare professional to weigh potential risks and benefits. - Liver impairment: use with caution and monitor liver function. - Neuropsychiatric symptoms: observe for mood changes, depression or suicidal thoughts. - Concomitant medications: review all drugs with a clinician to avoid interactions. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Montelukast may interact with several medicines; monitoring is advised.

Major Interactions (Avoid): - Ritonavir: can increase montelukast plasma concentrations. - Phenobarbital: may reduce montelukast effectiveness. - Carbamazepine: may lower drug levels and diminish therapeutic effect.

Moderate Interactions (Monitor Closely): - Fluconazole: may raise montelukast levels. - Erythromycin: can increase systemic exposure. - Warfarin: may alter INR and affect anticoagulation control.